Dr Liesl Butler: 2020 recipient
Dr Liesl Butler, Australian Centre for Blood Diseases (Melbourne).
Funding period: 2020-2023.
Project title: Development of improved biomarkers and targeted therapies for MPN.
Detailed project summary
Dr Liesl Butler is a junior haematologist pursuing a career in molecular pathology. She is currently undertaking translational research in the area, having recently commenced a Doctor of Philosophy (PhD) at the Australian Centre for Blood Diseases, Alfred Health. Her project will focus on the development of improved biomarkers and targeted therapy for the myeloproliferative neoplasms (MPNs).
MPNs are a group of chronic blood cancers characterised by excess production of mature blood cells, a heightened risk of thrombotic complications and increased likelihood of haematological progression to bone marrow fibrosis and/or transformation to acute myeloid leukaemia. Despite current treatments, such manifestations continue to cause significant morbidity and limit life expectancy; new drugs are urgently required.
Dr Butler will investigate the gene mutations and biological pathways that lead to the development of these diseases by undertaking tests in patient samples and mouse models. Her research will improve the ability to detect, treat and predict the course/outcome of MPNs.Posted on January 13th, 2020
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.